- Home
- BOLD vs IGC Comparison
BOLD vs IGC Comparison
Compare BOLD & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- IGC
- Stock Information
- Founded
- BOLD 2018
- IGC 2005
- Country
- BOLD United States
- IGC United States
- Employees
- BOLD N/A
- IGC N/A
- Industry
- BOLD
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- IGC Health Care
- Exchange
- BOLD Nasdaq
- IGC Nasdaq
- Market Cap
- BOLD 33.4M
- IGC 39.8M
- IPO Year
- BOLD 2024
- IGC N/A
- Fundamental
- Price
- BOLD $1.25
- IGC $0.39
- Analyst Decision
- BOLD Buy
- IGC Strong Buy
- Analyst Count
- BOLD 4
- IGC 2
- Target Price
- BOLD $4.00
- IGC $4.00
- AVG Volume (30 Days)
- BOLD 143.3K
- IGC 939.9K
- Earning Date
- BOLD 11-05-2025
- IGC 11-14-2025
- Dividend Yield
- BOLD N/A
- IGC N/A
- EPS Growth
- BOLD N/A
- IGC N/A
- EPS
- BOLD N/A
- IGC N/A
- Revenue
- BOLD N/A
- IGC $1,327,000.00
- Revenue This Year
- BOLD N/A
- IGC $3.54
- Revenue Next Year
- BOLD N/A
- IGC $15.12
- P/E Ratio
- BOLD N/A
- IGC N/A
- Revenue Growth
- BOLD N/A
- IGC 24.95
- 52 Week Low
- BOLD $1.00
- IGC $0.25
- 52 Week High
- BOLD $3.75
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- BOLD 40.98
- IGC 43.88
- Support Level
- BOLD $1.37
- IGC $0.38
- Resistance Level
- BOLD $1.52
- IGC $0.45
- Average True Range (ATR)
- BOLD 0.07
- IGC 0.02
- MACD
- BOLD -0.03
- IGC -0.00
- Stochastic Oscillator
- BOLD 6.25
- IGC 29.84
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.